Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data

Roche’s investigational non-small cell lung cancer candidate entrectinib has shown to reduce tumors in people with ROS1-positive NSCLC, including those whose disease had spread to the central nervous system, differentiating it from potential competitors.